Bangladesh Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Bangladesh Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Bangladesh Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: Sustained growth in Bangladesh ' s pharmaceutical and healthcare market will continue to translate in to commercial opportunities for drugmakers over the forecast period. A large generic medicine segment will continue to account for the lion 's share of the market, although patented products will continue to gain market share as affordability levels improve and healthcare development gradually materialises. In the medium term, the one-off doubling of government wages and an increase in budget allocation for the annual development program in FY2015/16 pose upside risks to market headlines driven by higher consumption. Over the long term, low-cost manufacturing will increase the market attractiveness and contribute to growing fixed investment and drug exports .

Headline Expenditure Projections

  • Pharmaceuticals: BDT154.24bn (USD1.99bn) in 2014 to BDT171.62bn (USD2.19bn) in 2015; +11.27% in local currency terms and +10.35% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: BDT437.86bn (USD5.65bn) in 2014 to BDT494.03bn (USD6.32bn) in 2015; +12.8% in local currency terms and +11.9% in US dollar terms. Forecast in line with last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (Bangladesh 2013-2019)
2013 2014 2015f 2016f 2017f 2018f 2019f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 1.778 1.989 2.195 2.395 2.621 2.865 3.128
Pharmaceutical sales, % of GDP 1.18 1.15 1.13 1.10 1.08 1.06 1.04
Pharmaceutical sales, % of health expenditure 35.9 35.2 34.7 34.4 34.1 34.0 33.9
Health spending, USDbn 4.955 5.646 6.318 6.967 7.678 8.429 9.219

Risk/Reward Index: In Q116 Bangladesh RRI score remains unchanged from last quarter at 41.8 out of 100. Bangladesh also retains its ranking position in BMI's RRI matrix, standing as the 15th most attractive market to pharmaceutical investors out of 19 markets in the Asia Pacific region. Bangladesh's score is driven by a large pharmaceutical market (market expenditure score of 10.0 out of 20) and rapid drug market expansion (sector value growth score of 8.4 out of 12), but dragged down by low levels of drug spending per capita (spending per capita score of 1.2 out of 12) and limited intellectual property protection (patent respect score of 1.4 out of 7).

Latest Updates

November 2015

  • Nepal and Bangladesh joined Uganda in demanding a permanent waiver on drug patents in showdown talks at the World Trade Organization (WTO) headquarters in Geneva, Switzerland, although the US is still refusing to allow a permanent waiver on drug patents.

  • UK-based drugmaker GlaxoSmithKline (GSK) plans to expand its business in Bangladesh with the aim of meeting increasing demand for pharmaceutical and healthcare products, intending to invest GBP40mn (USD61.36mn) within a year for the enhancement and expansion of its products, according to Ramil Burden, Vice President of GSK's Africa and developing countries division.

October 2015

  • Beximco is spearheading Bangladesh's pharmaceutical industry by taking advantage of Bangladesh's low-cost R&D base and creating a successful strategy to develop products with a focus on the export market; the latest data suggests Beximco's FY15 results will exceed BDT12bn (USD154mn) for the first time.

August 2015

  • Merck Sharp & Dohme (MSD) announced a strategic partnership with leading Bangladeshi pharmaceutical company Healthcare Pharmaceuticals Limited (HPL) that will enable MSD to introduce and distribute its best-in-class and first-in-class products for patients across Bangladesh.

BMI Economic View: Bangladesh's economy will likely grow by 6.5% in FY2015/16 (July-June), similar to the rate in FY2014/15, on the back of robust expansion in the industrial and services sectors. However, global economic slowdown and domestic security threats pose downside risks to our optimistic view.

BMI Political View: The stabilisation of the political climate is likely to boost investor confidence and provide support for Bangladesh's industrial and services sector over a multi-quarter horizon. However, we caution that domestic security threats pose downside risks to our view.

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Bangladesh 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Bangladesh 2011-2019)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Bangladesh 2011-2019)
28
Pharmaceutical Trade Forecast
29
Table: Pharmaceutical Trade Data And Forecasts (Bangladesh 2013-2019)
30
Table: Pharmaceutical Trade Data And Forecasts local currency (Bangladesh 2013-2019)
31
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Economic Analysis
32
Industry Risk Reward Ratings
37
Asia Pacific Risk/Reward Index
37
Bangladesh Risk/Reward Index
43
Rewards
43
Risks
43
Market Overview
45
Industry Trends And Developments
46
Epidemiology
46
Healthcare Sector
47
Healthcare Sector Financing and Budget Priority Areas (FY2015/2016)
52
Healthcare Infrastructure
54
Table: Healthcare Resources (Bangladesh 2009-2014)
54
Table: Healthcare Personnel (Bangladesh 2009-2014)
54
Table: Healthcare Activity (Bangladesh 2009-2014)
55
Research And Development
56
Table: Suggestions Made By University Of Dhaka's Faculty Of Pharmacy To Improve Pharmaceutical Research
57
Clinical Trials
58
Regulatory Development
60
Table: Steps To Establish A Pharmaceutical Manufacturing Unit And Obtain A Drug Manufacturing Licence
62
Intellectual Property Issues
62
Pricing And Reimbursement
64
Competitive Landscape
67
Pharmaceutical Industry
67
Company Developments
69
Pharmaceutical Distribution
70
Company Profile
71
Beximco Pharmaceuticals
71
Eskayef
74
Novartis
77
Renata
79
Sanofi
83
Square Pharmaceuticals
86
Demographic Forecast
89
Table: Population Headline Indicators (Bangladesh 1990-2025)
90
Table: Key Population Ratios (Bangladesh 1990-2025)
90
Table: Urban/Rural Population & Life Expectancy (Bangladesh 1990-2025)
91
Table: Population By Age Group (Bangladesh 1990-2025)
91
Table: Population By Age Group % (Bangladesh 1990-2025)
92
Glossary
94
Methodology
96
Pharmaceutical Expenditure Forecast Model
96
Healthcare Expenditure Forecast Model
96
Notes On Methodology
97
Risk/Reward Index Methodology
98
Index Overview
99
Table: Pharmaceutical Risk/Reward Index Indicators
99
Indicator Weightings
100

The Bangladesh Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Bangladesh Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Bangladesh pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Bangladesh, to test other views - a key input for successful budgeting and strategic business planning in the Bangladeshi pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Bangladeshi pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Bangladesh.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.